CytochromeP450 2D6 and Atomoxetine Metabolism

J Gordon Millichap

doi:10.15844/pedneurbriefs-24-10-1

CytochromeP450 2D6 and Atomoxetine Metabolism

Pediatric Neurology Briefs

Volume 24 (2010): Issue 10

By: J Gordon Millichap

Open Access

|Oct 2010

Abstract

The relation of cytochrome P450 2D6 (CYP2D6) activity to metabolism, response and adverse effects of atomoxetine was determined by CYP2D6 genotyping in 10 out of 100 children treated for attention deficit hyperactivity disorder at Amphia Hospital, Breda, The Netherlands.

References

ter Laak MA Temmink AH Koeken A van ’t Veer NE van Hattum PR Cobbaert CM Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity Pediatr Neurol 2010 Sep 43 3 159 62 10.1016/j.pediatrneurol.2010.04.004 20691935
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.15844/pedneurbriefs-24-10-1 | Journal eISSN: 2166-6482

Journal RSS Feed

Language: English

Page range: 73 - 74

Published on: Oct 1, 2010

Published by: Pediatric Neurology Briefs Publishers

In partnership with: Paradigm Publishing Services

Keywords:

Semiquantitative Gene,

Gastrointestinal,

Atomoxetine Metabolism

© 2010 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 24 (2010): Issue 10